ARCT: צמיחת הכנסות רבעונית Arcturus Therapeutics

Arcturus Therapeutics (ARCT) maintains positive asset momentum supported by its status as a scientific leader in LNP technologies. The quarterly revenue growth rate demonstrates the speed of scaling, with 19.40 representing the latest metric reading. Growth is driven by royalties from mRNA vaccine sales, while the operating model relies on full production outsourcing. The company focuses its efforts on R&D for the therapy of rare liver pathologies.
פילוחי נתונים אנליטיים מרוכזים עבור Arcturus Therapeutics Holdings Inc. (ARCT)

This metric is calculated as the percentage change in revenue from the current quarter to the previous one, measuring the fundamental resilience of the business and its speed of adaptation to market shocks. The value 19.40 reflects the revenue dynamics of Arcturus Therapeutics (ARCT), where the percentage growth in quarterly revenue confirms the commercial viability of the mRNA platform and its protection from price competition through technological superiority.